Shares of The Cooper Companies (COO.O) experienced a notable uptick today, crossing above the 5-day simple moving average, signaling a potential shift in momentum. This technical movement comes amid increasing pressure from Browning West, a significant investor advocating for governance reforms and a strategic overhaul due to the company's recent underperformance. Browning West's campaign highlights concerns over misaligned incentives and ineffective corporate structure, urging the board to appoint new directors to enhance operational focus and align management with long-term shareholder value. The firm believes that with the right changes, Cooper's stock could potentially double in value over the next few years, despite its current decade-low price-to-earnings ratio.
Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 80.370
Low
73.00
Averages
90.33
High
100.00
Current: 80.370
Low
73.00
Averages
90.33
High
100.00
Barclays
NULL -> Overweight
maintain
$97 -> $98
2026-01-26
New
Reason
Barclays
Price Target
$97 -> $98
AI Analysis
2026-01-26
New
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Cooper Companies to $98 from $97 and keeps an Overweight rating on the shares. The firm made minor changes to the company's model.
Goldman Sachs
Sell
maintain
$71 -> $73
2026-01-09
Reason
Goldman Sachs
Price Target
$71 -> $73
2026-01-09
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on Cooper Companies to $73 from $71 and keeps a Sell rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for COO
Unlock Now
Goldman Sachs
Sell
maintain
$64 -> $71
2025-12-08
Reason
Goldman Sachs
Price Target
$64 -> $71
2025-12-08
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on Cooper Companies to $71 from $64 and keeps a Sell rating on the shares. Cooper reported a relatively in line Q4, and adjusted EPS guidance was well ahead of consensus estimates, the analyst tells investors in a research note. While Cooper is making progress on improving the financial profile of the business, the overall trajectory of the top-line is relatively unchanged vs. the firm's prior estimates.
Citi
Neutral
maintain
$72 -> $88
2025-12-08
Reason
Citi
Price Target
$72 -> $88
2025-12-08
maintain
Neutral
Reason
Citi raised the firm's price target on Cooper Companies to $88 from $72 and keeps a Neutral rating on the shares. The company reported better than expected fiscal Q4 results after repeated misses, the analyst tells investors in a research note.
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
